ArMee Infotech's ₹300.00 crore initial public offering (IPO) opened for public subscription today, September 23, 2026, with a price band of ₹350 to ₹375 per share. As of 10:12 A.M. on the first day of bidding, the issue had been subscribed 0.01 times.
The IPO will remain open until September 25, 2026. The basis of allotment is expected to be finalised on September 28, 2026, and the shares are tentatively scheduled to be listed on the BSE and NSE on September 30, 2026.
The expected IPO schedule is as follows:
|
Event |
Date |
|
Subscription Opening Date |
23 September 2026 |
|
Subscription Closing Date |
25 September 2026 |
|
Basis of Allotment Date |
28 September 2026 |
|
Refund Initiation Date |
29 September 2026 |
|
Credit of Shares |
29 September 2026 |
|
Listing on BSE and NSE |
30 September 2026 |
Note: The allotment and listing dates are tentative and may be revised.
Explore other Upcoming IPOs on BSE and NSE.
[September 23, 2026, 10:12 A.M.]
|
Category |
Subscription (x) |
|
Qualified Institutional Buyers (QIBs) |
0.00x |
|
Non-Institutional Investors (NIIs) |
0.01x |
|
Retail Individual Investors (RIIs) |
0.02x |
|
Total |
0.01x |
The company intends to utilise the net proceeds from the fresh issue towards:
Incorporated in 2003, ArMee Infotech Limited provides IT infrastructure and managed IT services, while also operating in retail, renewable energy, and battery storage.
Headquartered in Ahmedabad, the company serves government, PSU, and private-sector clients. Its businesses include IT retail experience stores, solar EPC projects, power purchase agreement (PPA)-based solar development, and Battery Energy Storage Systems (BESS), with government and PSU projects contributing a significant share of revenue.
|
Particulars |
FY26 (in ₹ crore) |
FY25 (in ₹ crore) |
FY24 (in ₹ crore) |
|
Revenue from operations |
1,396.62 |
1,313.31 |
1,020.57 |
|
EBITDA |
75.63 |
58.64 |
71.58 |
|
Profit After Tax (PAT) |
45.47 |
41.67 |
50.13 |
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here